Ann: Remestemcel-L Improves Outcomes in Inflammatory Lung Disease, page-4

Key findings were:
• The greater the degree of inflammation, as measured by elevated CRP levels, the greater the signal of efficacy of remestemcel-L treatment in improving moderate to severe lung disease
• Significant improvements were observed in each of the pre-specified endpoints tested, forced expiratory volume, forced vital capacity, and the distance walked in the six-minute walk test (all p <0.01), with maximal effects on all parameters seen at four months
• In patients with the highest level of CRP (>4mg/L), those who received remestemcel-L were able to walk 55 meters further than placebo-treated patients in the six-minute walk test at four months (p=0.004); the six-minute walk test is a major independent predictor of mortality in COPD2
• The dose administered was well tolerated with no infusion-related toxicity and no identified safety concerns. Mesoblast Chief Medical Officer Dr Fred Grossman said: “